Shilpa Medicare Limited (SHILPAMED.BO)
INR 671.8
(1.65%)
INR 671.8
(1.65%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 9.37 Billion INR | 17.29% |
| 2022 | 7.99 Billion INR | 16.96% |
| 2021 | 6.83 Billion INR | -19.23% |
| 2020 | 8.45 Billion INR | 115.81% |
| 2019 | 3.91 Billion INR | 102.01% |
| 2018 | 1.94 Billion INR | 1.56% |
| 2017 | 1.91 Billion INR | -20.87% |
| 2016 | 2.41 Billion INR | 160.28% |
| 2015 | 927.64 Million INR | -2.07% |
| 2014 | 947.21 Million INR | -20.02% |
| 2013 | 1.18 Billion INR | -9.99% |
| 2012 | 1.31 Billion INR | 116.91% |
| 2011 | 606.52 Million INR | 7.16% |
| 2010 | 565.97 Million INR | -26.47% |
| 2009 | 769.73 Million INR | -31.69% |
| 2008 | 1.12 Billion INR | 27.64% |
| 2007 | 882.82 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 8.65 Billion INR | 0.0% |
| 2023 FY | 9.37 Billion INR | 17.29% |
| 2023 Q4 | 9.37 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 8.03 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 7.99 Billion INR | 0.0% |
| 2022 FY | 7.99 Billion INR | 16.96% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 8.35 Billion INR | 0.0% |
| 2021 Q4 | 6.83 Billion INR | 0.0% |
| 2021 FY | 6.83 Billion INR | -19.23% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 FY | 8.45 Billion INR | 115.81% |
| 2020 Q4 | 8.45 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 6.12 Billion INR | 0.0% |
| 2019 Q2 | 2.26 Billion INR | 0.0% |
| 2019 FY | 3.91 Billion INR | 102.01% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 3.91 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 1.94 Billion INR | 1.56% |
| 2018 Q4 | 1.94 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 1.15 Billion INR | 0.0% |
| 2017 FY | 1.91 Billion INR | -20.87% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q2 | 2.08 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q4 | 1.91 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 2.41 Billion INR | 160.28% |
| 2016 Q4 | 2.41 Billion INR | 0.0% |
| 2016 Q2 | 933.12 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 927.64 Million INR | -2.07% |
| 2015 Q4 | 927.64 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 1.85 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 1.7 Billion INR | 0.0% |
| 2014 Q4 | 947.21 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 947.21 Million INR | -20.02% |
| 2013 Q2 | 837.92 Million INR | 0.0% |
| 2013 FY | 1.18 Billion INR | -9.99% |
| 2013 Q4 | 1.18 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 Q2 | 829.2 Million INR | 0.0% |
| 2012 FY | 1.31 Billion INR | 116.91% |
| 2012 Q4 | 1.31 Billion INR | 0.0% |
| 2011 FY | 606.52 Million INR | 7.16% |
| 2011 Q4 | 606.52 Million INR | 0.0% |
| 2010 FY | 565.97 Million INR | -26.47% |
| 2009 FY | 769.73 Million INR | -31.69% |
| 2008 FY | 1.12 Billion INR | 27.64% |
| 2007 FY | 882.82 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alkem Laboratories Limited | 14.18 Billion INR | 33.913% |
| Alpa Laboratories Limited | 52.46 Million INR | -17766.932% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | -82.67% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -20285.99% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 85.899% |
| Bajaj HealthCare Limited | 3.32 Billion INR | -181.647% |
| Brooks Laboratories Limited | 56.41 Million INR | -16514.768% |
| Divi's Laboratories Limited | 30 Million INR | -31146.287% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 53.177% |
| Eris Lifesciences Limited | 27.81 Billion INR | 66.296% |
| FDC Limited | 205.18 Million INR | -4468.505% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 352.8 Million INR | -2556.997% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -838.89% |
| Hester Biosciences Limited | 2.44 Billion INR | -283.581% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 23.847% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -5366.46% |
| Granules India Limited | 13.15 Billion INR | 28.719% |
| Gufic Biosciences Limited | 3.32 Billion INR | -181.569% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -10384.158% |
| Indoco Remedies Limited | 6.71 Billion INR | -39.501% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -5539.581% |
| Ipca Laboratories Limited | 14.38 Billion INR | 34.829% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -384.615% |
| Lasa Supergenerics Limited | 220.76 Million INR | -4146.15% |
| Laurus Labs Limited | 25.77 Billion INR | 63.63% |
| Lupin Limited | 29.21 Billion INR | 67.917% |
| Mankind Pharma Limited | 2.07 Billion INR | -352.468% |
| Medicamen Biotech Limited | 308.17 Million INR | -2941.771% |
| Medico Remedies Limited | 80.5 Million INR | -11544.0% |
| Megasoft Limited | 1.47 Billion INR | -537.476% |
| NATCO Pharma Limited | 3.71 Billion INR | -152.529% |
| Procter & Gamble Health Limited | 95.6 Million INR | -9705.32% |
| Piramal Pharma Limited | 47.1 Billion INR | 80.099% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Sigachi Industries Limited | 1.43 Billion INR | -555.28% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -1432.933% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 71.366% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -1342.216% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -1193.189% |
| Unichem Laboratories Limited | 2.47 Billion INR | -278.721% |
| Wanbury Limited | 1.16 Billion INR | -704.732% |
| Windlas Biotech Limited | 36.41 Million INR | -25645.361% |
| ZIM Laboratories Limited | 1.08 Billion INR | -761.377% |
| Zydus Lifesciences Limited | 8.04 Billion INR | -16.562% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -54137.609% |
| Bal Pharma Limited | 1.39 Billion INR | -571.249% |
| Strides Pharma Science Limited | 25.16 Billion INR | 62.756% |
| Venus Remedies Limited | 413.3 Million INR | -2168.059% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | -228.62% |
| Nectar Lifesciences Limited | 6.35 Billion INR | -47.496% |
| Aarti Drugs Limited | 5.64 Billion INR | -66.124% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -2761.382% |
| Suven Life Sciences Limited | 7.09 Million INR | -131982.373% |
| Ind-Swift Limited | 10.13 Billion INR | 7.555% |
| Valiant Laboratories Limited | 767.08 Million INR | -1122.016% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | -148.21% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 7.327% |
| Themis Medicare Limited | 957.92 Million INR | -878.565% |
| Hikal Limited | 8.17 Billion INR | -14.654% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 76.693% |
| Sequent Scientific Limited | 4.87 Billion INR | -92.209% |
| Novartis India Limited | 69.7 Million INR | -13348.904% |
| Wockhardt Limited | 23.56 Billion INR | 60.213% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 74.416% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -213476.806% |
| Neuland Laboratories Limited | 953.89 Million INR | -882.695% |
| Morepen Laboratories Limited | 289.99 Million INR | -3132.464% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -2862.061% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -851.736% |